Article citationsMore>>

Ajeganova, S., De Becker, A. and Schots, R. (2020) Efficacy of High-Dose Anakinra in Refractory Macrophage Activation Syndrome in Adult-Onset Still’s Disease: When Dosage Matters in Overcoming Secondary Therapy Resistance. Therapeutic Advances in Musculoskeletal Disease, 12, 1-9.
https://doi.org/10.1177/1759720x20974858

has been cited by the following article:

• TITLE: Current Indications for IL-1 Inhibition in Rheumatology

  AUTHORS: Soukaina Zaher, Kawtar Nassar, Ahlam Ajerouassi, Wafae Rachidi, Saadia Janani

  KEYWORDS: Interleukin 1, Anti-Interleukin 1, Auto-Inflammatory Disease, Anakinra, Canakinumab, Rilonacept

  JOURNAL NAME: Open Journal of Rheumatology and Autoimmune Diseases, Vol.15 No.4, November 28, 2025

  ABSTRACT: Interleukin-1 pro-inflammatory cytokines orchestrate local and systemic inflammatory responses in several diseases. Three therapeutic agents for reducing the activities of IL-1 are currently available. Conditions effectively treated with IL-1 blocking agents range from classical rheumatic diseases to autoinflammatory syndromes. In addition, IL-1 antagonism is also effective against other very common diseases, namely cardiovascular disease and type 2 diabetes, which are also co-morbidities, frequently found in patients with rheumatic diseases. Therefore, inhibition of IL-1 may provide clinical benefits beyond the efficacy of osteoarticular manifestations. The purpose of this article is to review the indications for anti-interleukins 1 in rheumatology.